SCHEMBL10000323

SCHEMBL10000323

CCC(C)C(=O)c1cc(O)c(O)c(O)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.45
LMNA P02545 4/20 0.45
TDP1 Q9NUW8 3/20 0.45
MAPT P10636 3/20 0.45
ALDH1A1 P00352 2/20 0.45
FUT7 Q11130 2/20 0.45
TP53 P04637 2/20 0.45
MAPK1 P28482 2/20 0.45
CA12 O43570 1/20 0.45
CA1 P00915 1/20 0.45
CA2 P00918 1/20 0.45
CA3 P07451 1/20 0.45
SELL P14151 1/20 0.45
HPGD P15428 1/20 0.45
SELP P16109 1/20 0.45
FUT4 P22083 1/20 0.45
CA4 P22748 1/20 0.45
CA6 P23280 1/20 0.45
DPP4 P27487 1/20 0.45
CA5A P35218 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23764856 0.85 ESR1 (0.45) KDM4ELMNATDP1MAPTALDH1A1
SCHEMBL9407168 0.81 KDM4E (0.67) KDM4ELMNAMAPTCA12CA1
SCHEMBL9407166 0.81 KDM4E (0.67) KDM4ELMNAMAPTCA12CA1
SCHEMBL6357899 0.79 KDM4E (0.63) KDM4ELMNATDP1MAPTALDH1A1
SCHEMBL14595709 0.78 GAA (0.49) KDM4ELMNAALDH1A1CA12CA1
SCHEMBL18657871 0.78 CA5A (0.41) KDM4ELMNAMAPTALDH1A1TP53
SCHEMBL21584406 0.76 FBP1 (0.33) FBP1HKDC1
SCHEMBL24221611 0.76 LMNA (0.48) KDM4ELMNAMAPTALDH1A1HSD17B10
SCHEMBL24435635 0.76 ESR1 (0.44) KDM4ELMNATDP1MAPTALDH1A1
SCHEMBL22894532 0.75 TTR (0.39) LMNAMAPTALDH1A1TP53MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210251945-A1 COMPOUNDS AND PHARMACEUTICAL USES THEREOF SYNEURX INTERNATIONAL (TAIWAN) CORP. (TW) 2021-08-19 US disclosed
WO-2021155864-A1 COMPOUNDS AND PHARMACEUTICAL USES THEREOF SYNEURX INTERNATIONAL (TAIWAN) CORP. (CN) 2021-08-12 WO disclosed
US-8486898-B2 Compounds and method for inhibiting the activity of gelatinase and collagenase TAIPEI MEDICAL UNIVERSITY (TMU) (TW) 2013-07-16 US disclosed
US-20120022008-A1 Compounds and Method for Inhibiting the Activity of Gelatinase and Collagenase CHINA MEDICAL UNIVERSITY (TW) 2012-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210251945-A1 COMPOUNDS AND PHARMACEUTICAL USES THEREOF ACE, ACE2, FURIN KDM4E 4466/4885LMNA 2707/4885TDP1 3727/4885
US-20120022008-A1 Compounds and Method for Inhibiting the Activity of Gelatinase and Collagenase MMP2, MMP13, MMP1 KDM4E 2767/4885LMNA 639/4885TDP1 3187/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.